Please use this identifier to cite or link to this item: https://hdl.handle.net/10216/154873
Full metadata record
DC FieldValueLanguage
dc.creatorSousa, D
dc.creatorLima, RT
dc.creatorLopes-Rodrigues, V
dc.creatorGonzalez, E
dc.creatorRoyo, F
dc.creatorXavier, CPR
dc.creatorFalcón-Pérez, JM
dc.creatorVasconcelos, MH
dc.date.accessioned2023-11-20T09:29:48Z-
dc.date.available2023-11-20T09:29:48Z-
dc.date.issued2021
dc.identifier.issn2073-4409
dc.identifier.urihttps://hdl.handle.net/10216/154873-
dc.description.abstractCancer multidrug resistance (MDR) is one of the main challenges for cancer treatment efficacy. MDR is a phenomenon by which tumor cells become resistant to several unrelated drugs. Some studies have previously described the important role of extracellular vesicles (EVs) in the dissemination of a MDR phenotype. EVs’ cargo may include different players of MDR, such as microRNAS and drug-efflux pumps, which may be transferred from donor MDR cells to recipient drug-sensitive counterparts. The present work aimed to: (i) compare the ability of drug-sensitive and their MDR counterpart cells to release and capture EVs and (ii) study and relate those differences with possible distinct fate of the endocytic pathway in these counterpart cells. Our results showed that MDR cells released more EVs than their drug-sensitive counterparts and also that the drug-sensitive cells captured more EVs than their MDR counterparts. This difference in the release and capture of EVs may be associated with differences in the endocytic pathway between drug-sensitive and MDR cells. Importantly, manipulation of the recycling pathway influenced the response of drug-sensitive cells to doxorubicin treatment.
dc.description.sponsorshipThis article is a result of the project NORTE-01-0145-FEDER-000029, supported by Norte Portugal Regional Programme (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF). We thank Spanish MINECO (SAF2015-66312 to JMF) and for the REDIEX (Spanish Excellence Network in Exosomes) and the Severo Ochoa Excellence Accreditation (SEV-2016-0644). The authors thank the Portuguese Foundation for Science and Technology (FCT) for the PhD grant of DS (SFRH/BD/98054/2013). Cristina P.R. Xavier is supported by FCT and Fundo Social Europeu (FSE), through the post-doc grant SFRH/BPD/122871/2016. The authors also acknowledge the European COST Action-European Network on Microvesicles and Exosomes in Health and Disease (ME-HaD, BM1202) for short-term mission fellowship (ECOST-STSM-BM1202-150317-083396) and Grupo Español de investigacion en Vesiculas Extracelulares for GEIVEX mobility fellowship which allowed the work of DS in CICbioGUNE.
dc.language.isoeng
dc.publisherMDPI
dc.relationinfo:eu-repo/grantAgreement/FCT/FARH/SFRH%2FBD%2F98054%2F2013/PT
dc.relationinfo:eu-repo/grantAgreement/FCT/POR_NORTE/SFRH%2FBPD%2F122871%2F2016/PT
dc.relation.ispartofCells, vol.10(11):2886
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectCancer multidrug resistance
dc.subjectEndocytic pathway
dc.subjectExtracellular vesicles
dc.titleDifferent ability of multidrug-resistant and-sensitive counterpart cells to release and capture extracellular vesicles
dc.typeArtigo em Revista Científica Internacional
dc.contributor.uportoInstituto de Investigação e Inovação em Saúde
dc.identifier.doi10.3390/cells10112886
dc.relation.publisherversionhttps://www.mdpi.com/2073-4409/10/11/2886
Appears in Collections:I3S - Artigo em Revista Científica Internacional

Files in This Item:
File Description SizeFormat 
10.3390-cells10112886.pdf2.96 MBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons